Drug Profile
BMS 310705
Alternative Names: BMS310705Latest Information Update: 13 Oct 2010
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb; GBF
- Developer Bristol-Myers Squibb; Helmholtz Centre for Infection Research GmbH
- Class Antineoplastics; Epothilones; Macrolides
- Mechanism of Action Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 05 Aug 2005 A preclinical study has been added to the pharmacokinetics section
- 05 Nov 2003 A study has been added to the adverse events and Cancer therapeutic trials sections
- 04 Jul 2003 Data presented at the 39th Annual Meeting of the Society of Clinical Oncology (ASCO-2003) have been added to the adverse events, pharmacokinetics, Cancer therapeutic trials section